

**CRO Communiqué**  
**Keeping you informed about CRO progress**  
**June 2012**

**Top Enrolling Physicians for May 2012**

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	2	3.5	0	3.5
Dr. Biggers	3	0	3	3
Dr. Carlson	1	1	0.5	1.5
Dr. Ellis	2	2.3	0	2.3
Dr. Holden	2	2	0	2
Dr. Sciortino	1	1.3	0	1.3
Dr. Tummala	1	1	0	1
<b>TOTALS</b>	<b>12</b>	<b>11.1</b>	<b>3.5</b>	<b>14.6</b>

May 31, 2012 was the end of our grant year at CRO. We ended the year with 76.1 cancer control credits. This is 16.1 credits above our NCI assigned 60 credits. YEA! We earned 111.4 treatment credits which is 8.6 credits below our NCI's assigned 120 treatment credits. Thanks to all our investigators and staff for a wonderful grant year. A more detailed account of this past year activities will be coming out in our 2012 CRO Annual Report which will be distributed in a couple of weeks.

**CRO Web based monthly Educational Conference**

We were pleased with the attendance at our first monthly Educational conference. Our June meetings will be Monday, June 11 at 12noon and Tuesday, June 12 at 5pm. We highly encourage discussion and input from participants. Remember it is possible to login from home computers, iPhones, iPads, Blackberries and so on. CME's are available for attendance.

**Alliance Membership approved**

Our CCOP completed and submitted a Main Member application to Alliance, the merged group of NCCTG, CALGB and ACOSOG, on February 10, 2012. We were accepted as a member on May 4<sup>th</sup>. Our CCOP has had many enrollments to NCCTG and CALGB trials in the past. We look forward to giving our investigators access to these two groups' combined efforts through Alliance as well as providing more trials for our new surgical investigators.

**Study Profile**

NSABP B-49 "A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer" is our profile study this month. Patients must have unilateral invasive adenocarcinoma of the breast, be HER2-negative and undergone either a total mastectomy or breast-conserving surgery (lumpectomy). They must be randomized less than 84 day from surgery and have adequate cardiac, hepatic and kidney function.

**RTOG Audit**

On Wednesday, May 16<sup>th</sup> RTOG auditors were with us for their 3-year review of our documentation. No major deviations and only one minor deviation for late data submission was found. Yea! No corrective action plan is required.

**SWOG Audit**

CRO has been notified that SWOG will be here for their 3-year audit on August 22-23, 2012. This is our summer of research base audits. We are expecting GOG, MDAnderson, NSABP and Wake Forest to audit our charts before the year ends.

## **New Studies Approved in May 2012**

### **Opened at Cox and Mercy Springfield**

**GOG 0280** A Phase II Evaluation of the Potent, Highly Selective Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (IND#77840) (NSC #737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation

**NSABP B-49** A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

**SWOG S1105** Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer

### **Studies Permanently Closed to Enrollment at Cox & Mercy in May 2012**

**CALGB 70604** A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

### **Temporarily Closed to Accrual at Mercy & Cox**

**CTSU NCCTG N0733** Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 In Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane

**GOG 0260** A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer